MARKET

LLY

LLY

Lilly Eli & Co
NYSE
804.62
-16.57
-2.02%
After Hours: 804.60 -0.02 0.00% 19:59 07/26 EDT
OPEN
811.87
PREV CLOSE
821.19
HIGH
822.01
LOW
801.30
VOLUME
4.17M
TURNOVER
0
52 WEEK HIGH
966.10
52 WEEK LOW
443.25
MARKET CAP
764.72B
P/E (TTM)
118.43
1D
5D
1M
3M
1Y
5Y
1D
FDA issues warning on compounded versions of Novo Nordisk's semaglutide
U.S. FDA issues warning on compounded versions of Novo Nordisk's semaglutide. The agency says it has received reports of adverse events associated with the drug. The drug is the active ingredient in Novo's weight loss drug Wegovy and type 2 diabetes med Ozempic.
Seeking Alpha · 7h ago
Biohaven: Taldefgrobep Alfa Might Have A Place Beyond SMA Treatment
Seeking Alpha · 9h ago
AbbVie exits Alzheimer’s program on lack of differentiation
AbbVie exits Alzheimer’s program on lack of differentiation from currently approved drugs. The company has discontinued a Phase 2 program for its Alzheimer's therapy, ABBV-916. The drug is designed to target amyloid beta, a key protein in the disease.
Seeking Alpha · 10h ago
Analyzing Eli Lilly and Co In Comparison To Competitors In Pharmaceuticals Industry
Eli Lilly and Co is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. The company's Price to Earnings ratio of 120.94 is 3.07x above the industry average. Eli Lilly is experiencing remarkable growth in the Pharmaceuticals industry. Company has a higher Return on Equity than its peers.
Benzinga · 10h ago
Biogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side Events
The European Medicines Agency has adopted a negative opinion on the approval of Eisai and Biogen’s lecanemab. The companies are seeking approval for the treatment for early Alzheimer's disease. The EMA considered that the effect of Leqembi does not counterbalance the risk of serious side events.
Benzinga · 11h ago
Novo Nordisk: Better Buying Opportunities Ahead
Seeking Alpha · 11h ago
Biogen’s stock stumbles as Alzheimer’s drug is rejected by European regulators
MarketWatch · 13h ago
Prediction: This Is What Eli Lilly Stock Will Do Next
Shares of Eli Lilly are up more than 130% in the past year. The medicine company's stock has outpaced the S&P 500 and Nasdaq since January 2023. Shares of the company have soared 136% thanks to Lilly's dominance in the weight-loss space. Lilly's stock could be a good candidate for a stock split. The company is disrupting a major part of the healthcare space.
The Motley Fool · 13h ago
More
About LLY
Eli Lilly and Company is engaged in drug manufacturing businesses. The Company discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Humulin, Jardiance, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh and Taltz. Its neuroscience products include Cymbalta and Emgality. Its other products and therapies include Cialis and Forteo. The Company manufactures and distributes its products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer.

Webull offers Eli Lilly And Co stock information, including NYSE: LLY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LLY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LLY stock methods without spending real money on the virtual paper trading platform.